AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer

HIGHLIGHTS Amplia's highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic...

Related Keywords

Sydney ,New South Wales ,Australia ,United States ,Chicago ,Illinois ,United Kingdom ,Canada ,France ,Melbourne ,Victoria ,Australian ,American ,Chris Burns ,Nick Pavlakis ,Paul Timpson ,Garvan Institute Of Medical Research ,Prnewswire Amplia Therapeutics Limited ,American Society Of Clinical Oncology ,Linkedin ,Amplia Therapeutics ,Therapeutics Limited ,Garvan Institute ,Medical Research ,Meeting Abstracts ,American Society ,Clinical Oncology ,Managing Director ,Royal North Shore Hospital ,Focal Adhesion Kinase ,Clin Oncol ,